Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages 459-471

  Neschadim, Anton ^a   Pritzker, Laura B ^b   Pritzker, Kenneth P H ^b,c,d   Branch, Donald R ^c,e,f   Summerlee, Alastair J S ^g   Trachtenberg, John ^c,h,i   Silvertown, Joshua D ^a  

^a Toronto   (Canada)

^b Rna Diagnostics Inc   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e CANADIAN BLOOD SERVICES   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY OF GUELPH   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Androgen independence; Angiogenesis; Anti hormone therapy; Docetaxel; Prostate cancer; Relaxin; Relaxin antagonist; Tumor xenografts

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AT 001; DOCETAXEL; FORSKOLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINE 125; RADIOLIGAND; RELAXIN; RELAXIN RECEPTOR; RELAXIN RECEPTOR ANTAGONIST; RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; RECEPTOR; RELAXIN RECEPTORS; TAXOID;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANDROGEN THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; MOUSE; NOD SCID MOUSE; NONHUMAN; PROSTATE CANCER; RECEPTOR BINDING ASSAY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BINDING COMPETITION; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYME IMMUNOASSAY; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; TAXOIDS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903583009     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0088     Document Type: Article

References (51)

1. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ & Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57 205-225. (doi:10.1002/pros. 10290) (Pubitemid 37267805)
2. Carles J, Castellano D, Climent MA, Maroto P, Medina R & Alcaraz A 2012 Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clinical & Translational Oncology 14 169-176. (doi:10.1007/s12094-012-0780-8)
3. Cheng J, Kang X, Zhang S & Yeh ET 2007 SUMO-specific, protease 1 is essential for stabilization of HIF1a during hypoxia. Cell 131 584-595. (doi:10.1016/j.cell.2007.08.045) (Pubitemid 350007694)
4. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L et al. 2012 ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research 72 1494-1503. (doi:10.1158/0008-5472. CAN-11-3948)
5. Coffey RN, Morrissey C, Taylor CT, Fitzpatrick JM & Watson RW 2005 Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1 alpha mediated in prostate carcinoma cells. Cancer 103 1363-1374. (doi:10.1002/cncr.20918) (Pubitemid 40410730)
6. Escuin D, Kline ER & Giannakakou P 2005 Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Research 65 9021-9028. (doi:10.1158/0008-5472.CAN-04-4095) (Pubitemid 41377394)
7. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM & Agoulnik AI 2007 Relaxin promotes prostate cancer progression. Clinical Cancer Research 13 1695-1702. (doi:10.1158/1078-0432.CCR- 06-2492) (Pubitemid 46952934)
8. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T et al. 2010 Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocrine-Related Cancer 17 1021-1033. (doi:10.1677/ERC-10-0073)
9. Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D & Marignol L 2012 Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urologic Oncology 30 912-919. (doi:10.1016/j.urolonc.2010.08.015)
10. Fujioka M & Omori N 2012 Subtleties in GPCR drug discovery: a medicinal chemistry perspective. Drug Discovery Today 17 1133-1138. (doi:10.1016/j.drudis.2012.06.010)
11. Garmey EG, Sartor O, Halabi S & Vogelzang NJ 2008 Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clinical Advances in Hematology & Oncology 6 118-122 (127-132).
12. Gu J, Yamamoto H, Ogawa M, Ngan CY, Danno K, Hemmi H, Kyo N, Takemasa I, Ikeda M, Sekimoto M et al. 2006 Hypoxia-induced upregulation of angiopoietin-2 in colorectal cancer. Oncology Reports 15 779-783. (doi:10.3892/or.15.4.779)
13. Gulley J, Figg WD & Dahut WL 2003 Treatment options for androgenindependent prostate cancer. Clinical Advances in Hematology & Oncology 1 49-57.
14. Gunnersen JM, Roche PJ, Tregear GW& Crawford RJ 1995 Characterization of human relaxin gene regulation in the relaxin-expressing human prostate adenocarcinoma cell line LNCaP.FGC. Journal of Molecular Endocrinology 15 153-166. (doi:10.1677/jme.0.0150153)
15. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308. (doi:10.1210/er.2002-0032) (Pubitemid 38501396)
16. Hombach-Klonisch S, Bialek J, Trojanowicz B, Weber E, Holzhausen HJ, Silvertown JD, Summerlee AJ, Dralle H, Hoang-Vu C & Klonisch T 2006 Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. American Journal of Pathology 169 617-632. (doi:10.2353/ajpath.2006.050876) (Pubitemid 44156318)
17. Hossain MA, Samuel CS, Binder C, Hewitson TD, Tregear GW, Wade JD & Bathgate RA 2010 The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist. Amino Acids 39 409-416. (doi:10.1007/s00726-009- 0454-1)
18. Hsu SY, Kudo M, Chen T, Nakabayashi K, Bhalla A, van der Spek PJ, van Duin M & Hsueh AJ 2000 The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Molecular Endocrinology 14 1257-1271. (doi:10.1210/mend.14.8.0510)
19. Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS & Aghi MK 2012 Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Research 72 1773-1783. (doi:10.1158/0008-5472.CAN-11-3831)
20. Ivell R, Balvers M, Pohnke Y, Telgmann R, Bartsch O, Milde-Langosch K, Bamberger AM& Einspanier A 2003 Immunoexpression of the relaxin receptor LGR7 in breast and uterine tissues of humans and primates. Reproductive Biology and Endocrinology1114. (doi:10.1186/1477-7827-1-114)
21. Jeong CW, Yoon CY, Jeong SJ, Hong SK, Byun SS, Kwak C & Lee SE 2012 The role of hypoxia-inducible factor-1alpha and-2alpha in androgen insensitive prostate cancer cells. Urologic Oncology 31 1448-1456. (doi:10.1016/j.urolonc. 2012.03.022)
22. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B et al. 2013 A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discovery 3 1020-1029. (doi:10.1158/2159-8290. CD-13-0226)
23. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK & Agoulnik AI 2006 The role of relaxin in endometrial cancer. Cancer Biology & Therapy 5 71-77. (doi:10.4161/cbt.5.1.2289) (Pubitemid 43234981)
24. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R et al. 2011 Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. PNAS 108 3749-3754. (doi:10.1073/pnas.1014480108)
25. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG et al. 2013 An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discovery 3 1030-1043. (doi:10.1158/2159-8290.CD-13-0142)
26. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R et al. 2008 Inappropriate activation of androgen receptor by relaxin via b-catenin pathway. Oncogene 27 499-505. (doi:10.1038/sj.onc.1210671)
27. Mabjeesh NJ,Willard MT, Frederickson CE, Zhong H & Simons JW2003 Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 30-kinase/protein kinase B in prostate cancer cells. Clinical Cancer Research 9 2416-2425. (Pubitemid 36842080)
28. Millar WT & Smith JF 1983 Protein iodination using iodogen. International Journal of Applied Radiation and Isotopes 34 639-641. (doi:10.1016/0020-708X(83)90068-6)
29. Moore J & Wroblewski V 1992 Pharmacokinetics and metabolism of protein hormones. In Protein Pharmacokinetics and Metabolism, pp 93-126. Eds B Ferraiolo, M Mohler & C Gloff. USA: Springer.
30. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS & Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research 17 5913-5925. (doi:10.1158/1078-0432.CCR-11-0728)
31. Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ & Purohit A 2007 The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. British Journal of Cancer 97 1673-1682. (doi:10.1038/sj.bjc. 6604100)
32. Parissenti AM, Chapman JA, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B et al. 2010 Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Research and Treatment 119 347-356. (doi:10.1007/s10549-009-0531-x)
33. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S & Comoglio PM 2003 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 347-361. (doi:10.1016/S1535-6108(03) 00085-0) (Pubitemid 38340304)
34. Rapisarda A & Melillo G 2009 Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resistance Updates 12 74-80. (doi:10.1016/j.drup.2009.03.002)
35. Reis LO 2012 Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology 29 1948-1955. (doi:10.1007/s12032-011-9991-z)
36. Semenza GL 2002 HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in Molecular Medicine 8 S62-S67. (doi:10.1016/S1471- 4914(02)02317-1) (Pubitemid 34297081)
37. Silvertown JD, Summerlee AJ & Klonisch T 2003 Relaxin-like peptides in cancer. International Journal of Cancer 107 513-519. (doi:10.1002/ijc.11424) (Pubitemid 37296109)
38. Silvertown JD, Walia JS, Summerlee AJ & Medin JA 2006a Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery. Endocrinology 147 3797-3808. (doi:10.1210/en.2006-0028) (Pubitemid 44079384)
39. Silvertown JD, Ng J, Sato T, Summerlee AJ & Medin JA 2006b H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. International Journal of Cancer 118 62-73. (doi:10.1002/ijc.21288) (Pubitemid 41681581)
40. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ & Medin JA 2007 Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB Journal 21 754-765. (doi:10.1096/fj.06- 6847com) (Pubitemid 46348251)
41. Tashima LS, Mazoujian G & Bryant-Greenwood GD 1994 Human relaxins in normal, benign and neoplastic breast tissue. Journal of Molecular Endocrinology 12 351-364. (doi:10.1677/jme.0.0120351) (Pubitemid 24199704)
42. Thompson VC,Morris TG, Cochrane DR, Cavanagh J,Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME & Nelson CC 2006 Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66 1698-1709. (doi:10.1002/pros.20423) (Pubitemid 44893896)
43. Verhaegent M & Christopoulos TK 2002 Recombinant Gaussia luciferase. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. Analytical Chemistry 74 4378-4385. (doi:10.1021/ac025742k) (Pubitemid 35006424)
44. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R & de Vere White RW 2006 The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25 2082-2093. (doi:10.1038/sj.onc.1209246)
45. Voss MJ, Niggemann B, Zanker KS & Entschladen F 2010 Tumour reactions to hypoxia. Current Molecular Medicine 10 381-386. (doi:10.2174/ 156652410791317020)
46. Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergun S & Klein D 2012 Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochemistry and Cell Biology 137 391-401. (doi:10.1007/s00418-011-0898-8)
47. Xiao J, Huang Z, Chen CZ, Agoulnik IU, Southall N, Hu X, Jones RE, Ferrer M, Zheng W, Agoulnik AI et al. 2013 Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nature Communications 4 1953. (doi:10.1038/ncomms2953)
48. Xu Y, Chang E, Liu H, Jiang H, Gambhir SS & Cheng Z 2012 Proofof-concept study of monitoring cancer drug therapy with Cerenkov luminescence imaging. Journal of Nuclear Medicine 53 312-317. (doi:10.2967/jnumed.111.094623)
49. Yuan X, Cai C, Chen S, Yu Z & Balk SP 2013 Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene [in press]. (doi:10.1038/onc.2013.235)
50. Zhang Y, Castaneda S, Dumble M,Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y et al. 2011 Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Molecular Cancer Therapeutics 10 2309-2319. (doi:10.1158/1535-7163.MCT-11-0329)
51. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW & Semenza GL 1998 Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Research 58 5280-5284. (Pubitemid 28551099)